Skip to main
AVIR

Atea Pharmaceuticals (AVIR) Earnings Dates & Reports

Atea Pharmaceuticals (AVIR) Most Recent Earnings

Report Date
Period EndingQ4 2025
Est. EPS-$0.48
Actual EPS-$0.57
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Atea Pharmaceuticals (AVIR) Earnings per Share (EPS) History

Signup for full access
Browse free

Atea Pharmaceuticals (AVIR) Latest Earnings

The value each AVIR share was expected to gain vs. the value each share gained.

Atea Pharmaceuticals (AVIR) reported its most recent earnings on for Q4 2025, posting earnings per share (EPS) of -$0.57. This exceeded analysts' expectations of -$0.48 by 18.75%, marking a Miss.

For comparison, Atea Pharmaceuticals reported EPS of -$0.40 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of -$0.56.

Atea Pharmaceuticals (AVIR) Earnings History

Earnings
Est. EPSActual EPSSurprise
Q1 2026
-$0.56
Q4 2025
-$0.48-$0.57+18.75%
Q3 2025
-$0.43-$0.53+23.26%
Q2 2025
-$0.43-$0.44+2.33%
Q1 2025
-$0.41-$0.40-2.44%
View all

Atea Pharmaceuticals (AVIR) Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the Atea Pharmaceuticals’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

Atea Pharmaceuticals (AVIR) Earnings FAQs

Atea Pharmaceuticals (AVIR) last reported earnings on Mar 6, 2026 for Q4 2025, posting an EPS of -$0.57, which Miss the estimate of -$0.48 by 18.75%.

For Q4 2025, Atea Pharmaceuticals (AVIR) reported an EPS of -$0.57, missing analysts' estimate of -$0.48 by 18.75%.

For Q4 2025, Atea Pharmaceuticals (AVIR) Miss expectations with an actual EPS of -$0.57 vs. an estimated EPS of -$0.48.

Following the last earnings report on Mar 6, 2026, Atea Pharmaceuticals (AVIR)'s stock price moved — from — to —.

The next Atea Pharmaceuticals (AVIR) earnings call is scheduled for May. 11, 2026, where executives will discuss financial results and outlook.

Atea Pharmaceuticals (AVIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.